CLINICAL & PIPELINE·Drug Approval
FDA Approves NEFFY (Epinephrine Nasal Spray) by ARS PHARMS OPERATION: A New Dosage Form for Critical Care
ARS PHARMS OPERATION secured FDA approval for NEFFY (Epinephrine Nasal Spray) under NDA214697 on August 9, 2024, marking a significant Type 3 New Dosage Form approval. This innovative nasal delivery for Epinephrine, available in 1MG/SPRAY and 2MG/SPRAY, offers a novel administration route for a critical molecule. Procurement and business development teams must assess the strategic implications of this patient-friendly formulation on market dynamics and supply chain planning.
90-Day Activity